WEB DESK: The Drug Regulatory Authority of Pakistan (DRAP) has launched a nationwide crackdown on counterfeit and substandard pharmaceutical products after shocking health complaints from Khyber Pakhtunkhwa, Punjab, and Sindh giving rise to different batches of medicines and medical products described as counterfeit or substandard.
DRAP now issues recalls for Penbiotic injection, Carfen suspension, Novidat tablets, and many others. Some products, certain investigations reveal, are fictitious manufacturers that have hinted at hundreds of critical regulatory gaps.
Thus, to secure the above service, the National Regulatory Field Force (NRFF) of DRAP further elucidated in association with provincial drug control departments to hold market surveys to clear the circulation of hazardous products.
Pharmacists, chemists, and healthcare professionals have been instructed to immediately cease distribution or prescription of the flagged items, quarantine existing stocks, and report details with the supplier to the area’s drug inspectors.
Manufacturers of identified defective batches have been directed to recall their products, with field inspections underway to trace and eliminate these public health threats. Among the targeted products are substandard batches of folic acid and Cefradin capsules.
Through ratification, DRAP ensured public safety by laying down strict enforcement mechanisms and the collaboration of provincial health departments for the availment of safe and effective medicines.
Read More: Fog delays train arrivals nationwide
